Wednesday, September 24, 2008 2:37:37 PM
OT - "Do you boys ever question the wisdom of your love-in?
Exactly which 'love-in' would that be? If one is long RPRX he's guilty of participating in a 'love-in'? While I can't speak for pre-clinical, if you review all of my posts you won't find a single one that denys or overlooks the risks to a successful outcome for this company and Proellex. I have consistently stated that there are simply no FACTS out there YET that would suggest that Proellex will have a significant or deal-breaking safety issue. I have also always said that, LIKE ANY OTHER DRUG TRIAL, anything could happen, but that in that sense Proellex is simply running a normal FDA / clinical trials gauntlet, no different than any other. S**t can always happen, and no long that I've read has stated otherwise. If that's what you call a 'love-in', you clearly weren't around in the '60's.
And as to your condoning insider trading, I'll simply say your facile acceptance of it's occurrence stands in contrast to your outrage regarding the market research report. And to further clear the record, I didn't 'ask for free access' as you state. What I said textually was "Does anyone have access to this publication"?, and I'm curious what you think might be inappropriate about that question? And if someone did, and they wanted to share something with the board, wouldn't there be a few of the 'thousand shades of grey' available there, too?
As to naive, I must confess to being shocked... shocked I tell you, that you believe that "...such trading takes place.... I had no idea...
Exactly which 'love-in' would that be? If one is long RPRX he's guilty of participating in a 'love-in'? While I can't speak for pre-clinical, if you review all of my posts you won't find a single one that denys or overlooks the risks to a successful outcome for this company and Proellex. I have consistently stated that there are simply no FACTS out there YET that would suggest that Proellex will have a significant or deal-breaking safety issue. I have also always said that, LIKE ANY OTHER DRUG TRIAL, anything could happen, but that in that sense Proellex is simply running a normal FDA / clinical trials gauntlet, no different than any other. S**t can always happen, and no long that I've read has stated otherwise. If that's what you call a 'love-in', you clearly weren't around in the '60's.
And as to your condoning insider trading, I'll simply say your facile acceptance of it's occurrence stands in contrast to your outrage regarding the market research report. And to further clear the record, I didn't 'ask for free access' as you state. What I said textually was "Does anyone have access to this publication"?, and I'm curious what you think might be inappropriate about that question? And if someone did, and they wanted to share something with the board, wouldn't there be a few of the 'thousand shades of grey' available there, too?
As to naive, I must confess to being shocked... shocked I tell you, that you believe that "...such trading takes place.... I had no idea...
Recent RPRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 01:20:12 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 08:23:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2026 08:38:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2026 09:22:49 PM
- Form 13F-NT - Quarterly report filed by institutional managers, Notice • Edgar (US Regulatory) • 05/14/2026 06:29:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:14:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:12:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:10:50 PM
- Royalty Pharma to present at upcoming investor conferences • GlobeNewswire Inc. • 05/07/2026 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 01:04:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:31:54 AM
- Royalty Pharma reports first quarter 2026 results • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/30/2026 09:54:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/28/2026 09:00:16 PM
- Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation • GlobeNewswire Inc. • 04/21/2026 05:00:00 PM
- Royalty Pharma Declares Second Quarter 2026 Dividend • GlobeNewswire Inc. • 04/17/2026 12:30:00 PM
- Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 • GlobeNewswire Inc. • 04/15/2026 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 01:53:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/10/2026 08:11:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 08:10:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:58:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 08:55:58 PM
- Royalty Pharma signs $500M co-development agreement with J&J • IH Market News • 03/30/2026 12:28:19 PM
